- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

- Breakthrough designation is based on positive outcomes from clinical studies, and will advance the industry’s first next-generation digital therapeutic to treat memory and cognition in Alzheimer’s ...

New drugs for Alzheimer’s are finally coming onto the market after decades of failed attempts to slow its devastating progression. But startup Cognito Therapeutics is taking a drug-free approach to ...

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline. Cognito, based in Cambridge, Mass., is developing a headset that ...